Acumen Pharmaceuticals Analyst Ratings
Acumen Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 07/20/2023 | 100% | B of A Securities | → $14 | Reinstates | → Buy |
| 07/17/2023 | 85.71% | Cantor Fitzgerald | → $13 | Reiterates | Overweight → Overweight |
| 07/17/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/18/2023 | 85.71% | Cantor Fitzgerald | → $13 | Initiates Coverage On | → Overweight |
| 03/28/2023 | 85.71% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 03/28/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 02/02/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 11/15/2022 | 128.57% | Credit Suisse | $17 → $16 | Maintains | Outperform |
| 10/05/2022 | 214.29% | BTIG | $15 → $22 | Maintains | Buy |
| 07/15/2022 | 114.29% | BTIG | → $15 | Initiates Coverage On | → Buy |
| 06/30/2022 | 114.29% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 03/29/2022 | 142.86% | Credit Suisse | $26 → $17 | Maintains | Outperform |
| 01/21/2022 | 100% | B of A Securities | $16 → $14 | Upgrades | Neutral → Buy |
| 07/26/2021 | 285.71% | UBS | → $27 | Initiates Coverage On | → Buy |
| 07/26/2021 | 185.71% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
| 07/26/2021 | 271.43% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 285.71% | Stifel | → $27 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/09/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 07/20/2023 | 100% | B of A证券 | →$14 | 恢复 | →购买 |
| 07/17/2023 | 85.71% | 康托·菲茨杰拉德 | →$13 | 重申 | 超重→超重 |
| 07/17/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023年05月18日 | 85.71% | 康托·菲茨杰拉德 | →$13 | 开始承保 | →超重 |
| 03/28/2023 | 85.71% | 瑞士信贷 | $16→$13 | 维护 | 跑赢大盘 |
| 03/28/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | →购买 |
| 02/02/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | →购买 |
| 2022年11月15日 | 128.57% | 瑞士信贷 | $17→$16 | 维护 | 跑赢大盘 |
| 10/05/2022 | 214.29% | BTIG | $15→$22 | 维护 | 买 |
| 07/15/2022 | 114.29% | BTIG | →$15 | 开始承保 | →购买 |
| 2022/06/30 | 114.29% | HC Wainwright公司 | →$15 | 开始承保 | →购买 |
| 03/29/2022 | 142.86% | 瑞士信贷 | $26→$17 | 维护 | 跑赢大盘 |
| 2022年01月21日 | 100% | B of A证券 | $16→$14 | 升级 | 中性→购买 |
| 07/26/2021 | 285.71% | 瑞银集团 | →$27 | 开始承保 | →购买 |
| 07/26/2021 | 185.71% | B of A证券 | →$20 | 开始承保 | →中性 |
| 07/26/2021 | 271.43% | 瑞士信贷 | →$26 | 开始承保 | →跑赢大盘 |
| 07/26/2021 | 285.71% | Stifel | →$27 | 开始承保 | →购买 |
What is the target price for Acumen Pharmaceuticals (ABOS)?
Acumen PharmPharmticals(ABOS)的目标价是多少？
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $15.00 expecting ABOS to rise to within 12 months (a possible 114.29% upside). 10 analyst firms have reported ratings in the last year.
慧聪制药(纳斯达克代码：ABOS)的最新目标价是由HC Wainwright&Co.于2023年8月9日报道的。这家分析公司将目标价定为15美元，预计ABOS将在12个月内上涨至(可能上涨114.29%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
Acumen PharmPharmticals(ABOS)的最新分析师评级是多少？
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by HC Wainwright & Co., and Acumen Pharmaceuticals reiterated their buy rating.
分析师对Acumen PharmPharmticals(纳斯达克代码：ABOS)的最新评级由HC Wainwright&Co.提供，Acumen制药公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Acumen PharmPharmticals(ABOS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Acumen制药的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Acumen制药的上一次评级是在2023年8月9日提交的，所以你应该预计下一次评级将在2024年8月9日左右提供。
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
分析师对Acumen PharmPharmticals(ABOS)的评级正确吗？
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a reiterated with a price target of $0.00 to $15.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $7.00, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Acumen PharmPharmticals(ABOS)评级被重申，目标价在0.00美元至15.00美元之间。Acumen PharmPharmticals(ABOS)目前的交易价格为7.00美元，在分析师的预测范围内。